SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-21-004620
Filing Date
2021-11-15
Accepted
2021-11-15 16:33:25
Documents
52
Period of Report
2021-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q ikt-20210930.htm   iXBRL 10-Q 1414149
2 EX-31.1 ikt-ex31_1.htm EX-31.1 15610
3 EX-31.2 ikt-ex31_2.htm EX-31.2 15629
4 EX-32.1 ikt-ex32_1.htm EX-32.1 13018
5 EX-32.2 ikt-ex32_2.htm EX-32.2 13018
  Complete submission text file 0000950170-21-004620.txt   4353697

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT ikt-20210930_cal.xml EX-101.CAL 25768
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT ikt-20210930_lab.xml EX-101.LAB 255318
8 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT ikt-20210930.xsd EX-101.SCH 31216
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT ikt-20210930_pre.xml EX-101.PRE 182889
10 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT ikt-20210930_def.xml EX-101.DEF 83728
11 EXTRACTED XBRL INSTANCE DOCUMENT ikt-20210930_htm.xml XML 545208
Mailing Address 3350 RIVERWOOD PARKWAY SE, SUITE 1900 ATLANTA GA 30339
Business Address 3350 RIVERWOOD PARKWAY SE, SUITE 1900 ATLANTA GA 30339 678-392-3419
Inhibikase Therapeutics, Inc. (Filer) CIK: 0001750149 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39676 | Film No.: 211411435
SIC: 2836 Biological Products, (No Diagnostic Substances)